Comparison of the effect of intradermal injection of tranexamic acid versus microneedling plus topical tranexamic acid in the treatment of patients with melasma

Comparison between the efficacy of multiple microinjections of tranexamic acid (100 mg/ml) with microneedling and topical tranexamic acid (100 mg/ml) in the treatment of melasma in patients with symmetrical face melasma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201205049603N1

Enrollment

Registered

2021-02-08

Start date

2020-11-30

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma.

Interventions

Intervention 1: Intervention group 1: includes 13 patients whose right side of the face is 100 mg / ml tranexamic acid solution is topically apllied on the skin surface then microneedling (inopen made

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Having Fitzpatrick II-IV skin type with symmetrical melasma diagnosed by a dermatologist Patient willingness to participate in the study

Exclusion criteria

Exclusion criteria: Patients receiving OCP, anticonvulsants, antidepressants, and thyroid medications over the past 12 months Existence of coagulation disorder or anticoagulant use in the patient Patient sensitivity to the studied compounds Existence of active herpes, facial warts or active dermatosis Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
MASI scoring for photographs of patients with melasma. Timepoint: Before the start of the study and 4 weeks after the end of treatment. Method of measurement: MASI score for photography.	—

Secondary

Measure	Time frame
Patient satisfaction with treatment. Timepoint: 4 weeks after treatment. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Alizadeh

Esfahan University of Medical Sciences

maryam.alizadeh87@gmail.com+98 31 3668 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026